Round 2 for Genentech
639887
Learn a lesson or two from the drugmaker's dance with the FDA.
398264
Just been doing some heavy translation from German to English. Which lead to writing a simple command line tool for translating via Google - waste time to save time in other words. Getting a prototype up from scratch took about 15 minutes (which sheds a light on blog spam I guess). Have cleaned it up a bit and dropping it here in case anyone can use it.
383170
Human Genome Sciences, Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL Receptor 1) in patients with advanced ...
763441
Genentech Inc. (DNA.N: Quote, Profile, Research) on Wednesday posted a 50 percent rise in quarterly profit and raised its full-year earnings forecast on strong sales of
21427
roundup Plus: Sun expands pay-as-you go supercomputing...SGI works on Linux performance software...Good Technology supported by HP, Samsung.
405065
Google buys a mapquest of its own. Also: Sharp takes us to the future of television in 3-D & hellip;.  PayPal finds a way to make amends for mistakes & hellip;. and more.
347122
UK registry owner holds second EGM UK registry owner Nominet is this morning holding its second extraordinary general meeting in a year in Oxford in an effort to expand its business and modernise its processes.â¦
240917
Genentech Inc.  on Wednesday said second-quarter profit rose 41 percent, fueled by growth from key cancer drugs Avastin and Rituxan, and it boosted its full-year profit forecast.
300949
23andMe has been much talked about. Here's what that little start-up is going to be doing.
704563
Genentech's cancer drug Avastin helped patients with advanced kidney cancer live twice as long as those on standard therapy alone, according to a study released on Saturday.
655606
Cancer patients treated with Genentech  Inc.'s colon cancer drug Avastin along with the chemotherapy  regimen FOLFOX4 lived longer than patients treated with the  chemotherapy alone in a late-stage clinical trial, the biotech  company said on Monday.
225228
BOSTON (CBS.MW) - Shares of Genentech were halted on Monday as the company announced that its oncology drug Avastin had been shown to extend the lives of some patients stricken with advanced colorectal cancer.
360148
Tycho:  I should have all the science lined up by the end of the week, ready to stuff into the piano black lozenge I've obtained to celebrate my return to personal computing.  Wish me luck; I've never before had the opportunity to fry four processors at once.       I know things.  Specifically, things that may be of interest to you.  For example, I know if playing Eye of Judgment online is an onerous as it might seem.  It is not!  I cannot express my relief.    Well, let's try.  In my last, vast expose, I broke down a card's unique language and expressed some misgivings about online play - ultimately just accepting it, because what they're trying to do is so weird that there's no prior art.  Essentially, you "register" your thirty card deck with the system itself, where it is stored and named for future use.  This process is extremely straightforward:  it is simply a matter of you laying your cards anywhere on the mat, a few at a time.  It will probably take two minutes if you really keep on it.  Then, you jump online, choose what nation you want to play for, and track down a partner.  At this point, the game will "draw" you your five card hand by showing you the card art onscreen.  You get one Mulligan (or redraw), but if you like your hand you move into the game proper.  We laid out our deck by element, face up, and this smoothed the turn to turn process considerably.      In the build we have, and I hope this is changed for release, it shows you these cards in a single file line without their name or text - just the art.  Once you got familiar with these images, slightly modified from their card format, it's pretty quick - but the names should be displayed on this screen.  You can use the controller to pull up the names, but let's be serious - at no point should the player be forced to interact with a mundane controller once the game is underway.     You should know that the game really wants a well-lit environment.  You don't need a flare gun or anything, but we didn't have what we needed before and certain squares would slow down the game flow with partial reads that would only resolve after several attempts and minute card adjustments.  I should state that here in the office, we removed all the overhead lights, installing a single track of illumination that we point at the ceiling, where lights used to be.  We tend to transform any place we live into a cave.  So, our scenario might be somewhat atypical.    Also, I know if playing Rock Band with all the instruments off of a USB hub is onerous.  You will be happy to know that it is not - we played said instruments spread out on an actual stage, and found it more than satifactory.  The reality is that the drum kit already needs its own wire, so it isn't as though the future had actually arrived anyway.  Plus, the mic isn't wireless either. This makes the contrived brouhaha over wired guitars a fairly transparent traffic ploy.    This is a matter quite apart from Microsoft's reticence to play ball with unique, third party hardware.  And when I say "play ball," I'm taking about the shakedown operation they've got going licensing their wireless technology, which either makes products for their system more expensive or (in the salient case of Rock Band) results in them bundling a wired controller for the same price as a wireless one on a competitor's system.  This is the last holiday they can get away with this sort of thing...  right?
608900
Biotechnology company Genentech Inc   said on Monday its fourth-quarter profit rose 6.4  percent, but sales of several drugs, including blockbuster  cancer drug Avastin, fell short of investor expectations,  sending the company's shares lower.
683680
Genentech said a low dose of its cancer drug worked just as well as a more expensive high dose in a clinical trial.
750633
The biotech giant is hit with a subpoena requesting documents related to the promotion of Rituxan, its best-selling drug. Just two days before its third-quarter earnings release, biotechnology pioneer Genentech
257114
Genentech Inc. (DNA.N: Quote, Profile, Research) on Wednesday said third-quarter earnings rose 50 percent, spurred by growth in new colon cancer treatment Avastin and strong sales of its